

# CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS



PHM153A  
January 2014

Usha Nagavarapu  
*Project Analyst*

ISBN: 1-56965-671-1

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
INTENDED AUDIENCE	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	4
ABOUT THE AUTHOR	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH ONLINE SERVICES	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, 2012-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 CIRCULATING TUMOR CELLS	10
CANCER	10
RECENT ADVANCES IN TECHNOLOGY	10
INVASIVE POWER	11
CIRCULATING TUMOR CELL	11
PHENOTYPIC CHARACTERISTICS	11
CTC CLUSTERS	12
CTC DETECTION	12
CANCER STEM CELLS (CSC)	13
<i>TABLE 1 CATEGORIES OF STEM CELLS</i>	14
<i>TABLE 2 PRODUCT CATEGORIES</i>	15
CIRCULATING TUMOR CELLS - POTENTIAL USES	15
<i>TABLE 3 KEY FACTORS OF CTC'S</i>	16
What Are Circulating Tumor Cells?	16
Biology and Characteristics of CTCs	17
<i>TABLE 4 CIRCULATING TUMOR CELLS - FEATURES</i>	18
PROLIFERATIVE ACTIVITY	18
EPITHELIAL MARKER GENES ON CIRCULATING TUMOR CELLS	19
CTCs as Biomarkers	20
Biomarker Qualification Program	21
Epithelial to Mesenchymal Transition	21
CIRCULATING TUMOR CELLS AND STEM CELL-LIKE PHENOTYPE	22
CTCS AND PRIMARY TUMOR CELLS: COMPARISON	22
METASTASIS	23
The Metastatic Process	23
FUTURE DIRECTIONS	24
<i>TABLE 5 METASTATIC CASCADE</i>	24
METASTATIC DEVELOPMENT IN CANCER PATIENTS	25

<b>TOPIC</b>	<b>PAGE NO.</b>
CIRCULATING TUMOR CELL MIGRATION	25
IMPORTANT MARKERS OF DISTANT METASTASIS	25
CIRCULATING TUMOR CELL DETECTION	25
<i>TABLE 6 EPCAM-BASED ASSAYS</i>	26
CHALLENGES FOR DETECTION	26
THE CLINICAL APPLICATION OF CIRCULATING TUMOR DNA	27
CIRCULATING TUMOR CELLS AS PREDICTOR OF RESPONSE TO THERAPY	27
MEASUREMENT OF CTCS - APPLICATIONS	28
CONCLUSION	28
<i>TABLE 7 CTC DETECTION - ADVANTAGES</i>	29
CHAPTER 4 INCIDENCE OF CANCER	31
WORLDWIDE GROWTH IN THE INCIDENCE OF CANCER	31
<i>TABLE 8 CANCER - KEY FACTS</i>	32
CAUSES OF CANCER	32
<i>TABLE 9 CANCER CAUSES</i>	33
RISK FACTORS FOR CANCERS	33
BURDEN OF CANCER	33
AVOIDING RISK FACTORS	33
<i>TABLE 10 CANCER CAUSING FACTORS</i>	34
Prevention Strategies	34
EARLY DETECTION	34
Early Diagnosis	34
Screening	34
<i>TABLE 11 CANCER SCREENING METHODS</i>	35
TREATMENT	35
Treatment of Early-Detectable Cancers	35
Treatment of Other Cancers with Potential for Cure	35
PALLIATIVE CARE	35
Palliative Care Strategies	36
WORLD HEALTH ORGANIZATION RESPONSE	36
<i>TABLE 12 NONCOMMUNICABLE DISEASES ACTION PLAN</i>	36
WORLD CANCER STATISTICS	36
<i>TABLE 13 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)</i>	37
<i>FIGURE 1 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)</i>	37
<i>TABLE 14 ESTIMATED GLOBAL CANCER INCIDENCE, 2008 (THOUSANDS)</i>	38
CANCER AND THE GLOBAL IMPACT	38
Prevalence	39
Global Patterns	39
THE FUTURE OF CANCER	40
<i>TABLE 15 INCREASE IN CANCER BURDEN - FACTORS</i>	41
Common Types of Cancer	42
<i>TABLE 16 THE MAIN TYPES OF CANCER AND ASSOCIATED MORTALITY</i>	43
<i>TABLE 17 GENERAL GLOBAL CANCER INCIDENCE BY TYPE</i>	43
<i>TABLE 18 GLOBAL INCIDENCE OF CANCER BY TYPE, 2008 (THOUSANDS/%)</i>	44
Global Incidence in Men	45
<i>TABLE 19 CANCER INCIDENCE IN MEN, 2008 (THOUSANDS/%)</i>	45

<b>TOPIC</b>	<b>PAGE NO.</b>
Global Incidence in Women	46
<i>TABLE 20 CANCER INCIDENCE IN WOMEN, 2008 (THOUSANDS/%)</i>	46
Developed Countries	47
<i>TABLE 21 GLOBAL INCIDENCE OF CANCER IN DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000, 2008</i>	47
Men	48
<i>TABLE 22 GLOBAL INCIDENCE OF CANCER IN MEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008</i>	48
Incidence in Women	49
<i>TABLE 23 GLOBAL INCIDENCE OF CANCER IN WOMEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008</i>	49
UNITED STATES CANCER INCIDENCE	50
<i>TABLE 24 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013</i>	50
<i>FIGURE 2 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013</i>	50
BREAST CANCER	51
<i>TABLE 25 GLOBAL BREAST CANCER FACTS</i>	51
<i>TABLE 26 BREAST CANCER IN THE UNITED STATES</i>	52
COLORECTAL CANCER	53
<i>TABLE 27 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN MEN, 2008</i>	54
<i>TABLE 28 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN WOMEN, 2008</i>	55
U.S. Incidence	55
<i>TABLE 29 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013</i>	55
<i>FIGURE 3 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013</i>	56
PROSTATE CANCER	56
<i>TABLE 30 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF PROSTATE CANCER, 2008</i>	56
Westernization Trends	57
<i>TABLE 31 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)</i>	58
<i>FIGURE 4 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)</i>	58
Prostate Cancer Mortality	60
<i>TABLE 32 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008</i>	60
<i>FIGURE 5 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008</i>	61
Prostate Cancer a Burden Globally	61
<i>TABLE 33 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030 (NUMBER)</i>	62
<i>FIGURE 6 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030 (NUMBER)</i>	62
Prostate Cancer and the U.S.	63
<i>TABLE 34 PROSTATE CANCER CASES AND DEATHS IN THE U.S. 2008-2011 (NUMBER)</i>	63
<i>FIGURE 7 PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011 (NUMBER)</i>	63
<i>TABLE 35 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030 (NUMBER)</i>	64

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 8 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030 (NUMBER)</i>	64
<i>TABLE 36 PROSTATE CANCER INCIDENCE RATES IN THE U.S. BY RACE, 2005-2009 (PER 100,000 MEN)</i>	65
<i>TABLE 37 ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030 (NUMBER)</i>	65
<i>FIGURE 9 ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030 (NUMBER)</i>	66
Prostate Cancer Mortality Rates in the U.S.	66
<i>TABLE 38 MORTALITY RATES BY RACE IN U.S., 2005-2009</i>	66
Prostate Cancer in Canada	67
<i>TABLE 39 ESTIMATED PROSTATE CANCER IN CANADA, 2012 (NUMBER)</i>	67
Prostate Cancer in Europe	67
<i>TABLE 40 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION, 2008</i>	68
<i>FIGURE 10 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008</i>	68
Prostate Cancer in the United Kingdom	69
<i>TABLE 41 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION)</i>	70
<i>FIGURE 11 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION)</i>	71
Prostate Cancer in Asia	71
CONCLUSIONS	72
CHAPTER 5 TECHNOLOGIES	74
FINDING CIRCULATING TUMOR CELLS	74
<i>TABLE 42 POTENTIAL APPLICATIONS OF CTC-BASED DIAGNOSTICS</i>	74
CURRENT CTC DETECTION AND ISOLATION METHODS	75
NEW TECHNOLOGIES FOR THE DETECTION	75
CANCER PROGNOSIS	76
Carcinoma - CTC and the Metastatic Cascade	77
How many CTCs?	77
The Biological Characteristics of CTC	77
<i>TABLE 43 CLINICAL RELEVANCE OF CTC</i>	78
Cancer Dissemination	78
CTC DETECTION TECHNIQUES - REQUIREMENTS	78
<i>TABLE 44 CTC ENRICHMENT METHODS</i>	78
ENRICHMENT METHODS	79
<i>TABLE 45 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ENRICHMENT</i>	80
Morphology-Based Enrichment Methods	80
Cell Separation Based on Density Gradient Centrifugation	80
Size-Based Cell Enrichment by Filtration	81
Immunomagnetic Separation Techniques	81
The RosetteSep-Applied Imaging Rare Event (RARE) Method	82
MagSweeper	83
DETECTION METHODS	83

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 46 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ANALYSIS</i>	84
Immunocytochemical Approaches	84
Fiber-Optic Array Scanning Technology	85
Laser Scanning Cytometer	85
Multiphoton Intravital Flow Cytometry	85
COMBINED ENRICHMENT AND DETECTION METHODS	85
<i>TABLE 47 ENUMERATION TECHNIQUES</i>	86
CellSearch System	86
Microfluidic Devices	87
Microfluidic Chips	87
EPISPOT	88
AdnaTest	88
TelomeScan	89
CTC Chip	89
<i>TABLE 48 FUNCTIONAL ASSAYS</i>	90
NUCLEIC ACID-BASED METHODS	91
Limitations	92
Flow Cytometry	92
Image-Based Approaches	93
Reverse-Transcriptase PCR	93
CLINICAL TESTING	94
CTC Analysis in Cancer Patients	94
CTC Analysis in Patients with Metastatic Disease	95
SUMMARY	96
<i>TABLE 49 KEY FACTS ABOUT CIRCULATING TUMOR CELLS</i>	97
NEW EMERGING TECHNOLOGIES	97
<i>TABLE 50 MICRO-COUNT FEATURES A NEW TECHNOLOGY</i>	98
Herringbone-Chip (HB-Chip)	98
Future Directions	99
CHAPTER 6 CIRCULATING TUMOR CELLS AND CANCER DIAGNOSTICS	101
<i>TABLE 51 CTC ASSAY PRE-ANALYTICAL VALIDATION CONSIDERATIONS</i>	102
<i>TABLE 52 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS</i>	102
<i>TABLE 53 CTC ASSAY POST-ANALYTICAL VALIDATION CONSIDERATIONS</i>	103
USE OF CTC'S FOR DIAGNOSIS	103
<i>TABLE 54 CURRENT ENRICHMENT ASSAYS FOR CTCS</i>	105
<i>TABLE 55 CTC ENUMERATION ASSAYS</i>	108
CURRENT METHODS AND APPLICATIONS	110
CTC Chip	110
<i>TABLE 56 CHARACTERIZATION ASSAYS FOR CTCS</i>	111
IVD Diagnostics	112
<i>TABLE 57 KEY FEATURES-IVD CTC TESTS</i>	112
<i>TABLE 58 TUMOR TYPES: PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010</i>	112
<i>FIGURE 12 TUMOR TYPES - PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010</i>	113
IVDiagnosics Customized Aptamer Selection Service	114
IVDiagnosics CTC Capture	114
IVDiagnosics CTC Human Genetics	114

<b>TOPIC</b>	<b>PAGE NO.</b>
Biocept	114
CIRCULATING TUMOR CELLS IN PROSTATE CANCER: CASE STUDIES	114
<i>TABLE 59 PROSTATE CANCER DIAGNOSIS AND ROLE OF CTC'S</i>	115
CTC IN COMPANION DIAGNOSTICS	115
<i>TABLE 60 CURRENT DIAGNOSTIC METHODS</i>	115
ApoCell	116
<i>TABLE 61 APOSTREAM KEY FEATURES</i>	116
ApoStream CTC Imaging	116
Clariant Launches Biocept's OncoCEE-BR Test	117
Canopus Bioscience	117
<i>TABLE 62 CANOPUS BIOSCIENCE TECHNOLOGY - BENEFITS</i>	118
Ikonisys	118
<i>TABLE 63 CELLOPTICS' CANCER APPLICATION</i>	118
Technique	119
<i>TABLE 64 CELLOPTICS' KEY FEATURES - ENRICHMENT</i>	119
<i>TABLE 65 CELLOPTICS' KEY FEATURES - LABELING</i>	119
<i>TABLE 66 CELLOPTICS' KEY FEATURES - DETECTION</i>	120
RAREcells Diagnostics	120
<i>TABLE 67 ISET TEST - SPECIFICATIONS</i>	120
NEWER TECHNOLOGIES IN DEVELOPMENT	121
OriGene Technologies	121
Protein Microarray and Its Application	121
Viator Technologies	121
Photoacoustic Detection and Capture of CTCs	121
Micro Technologies	121
Interrogate Signaling in Single Cells	121
NanoVelcro	122
Embedded Microchips	122
MOLECULAR ANALYSES OF CTC	122
The Ephesia Magnetic Arrays Technology	122
New "Biopsy in a Blood Test"	122
CONCLUSIONS	124
CHAPTER 7 CTCS IN CLINICAL TRIALS	126
CTC DIAGNOSTICS	126
CIRCULATING TUMOR CELL TECHNOLOGY	126
POTENTIAL THERAPEUTIC USES OF CIRCULATING TUMOR CELLS	127
CHALLENGES IN THE DETECTION OF CIRCULATING TUMOR CELLS	128
CTC'S AS CLINICAL BIOMARKERS	129
PCR-BASED MARKERS	130
Carcinoma Cells	130
CIRCULATING TUMOR CELLS IN CANCER - CURRENT STATUS	130
Breast Cancer	130
STIC CTC METABREAST (France)	131
SWOG 0500 (USA)	132
CirCe01 (France)	132
Treat CTC (Europe)	133

<b>TOPIC</b>	<b>PAGE NO.</b>
DETECT III (Germany)	134
PROGNOSTIC AND PREDICTIVE VALUE OF CIRCULATING TUMOR CELLS (CTC'S)	135
Breast Cancer	135
Pancreatic Cancer	136
Lung Cancer	137
CTC'S IN CLINICAL CANCER MANAGEMENT	137
<i>TABLE 68 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT</i>	137
Clinical Impact of CTCs	138
EXISTING TECHNOLOGIES IN CLINICAL TRIALS	138
Cell Search and AdnaTest - Comparision	138
Size- and Biomechanical Properties-Based Isolation	140
CLINICAL STUDIES USING CELLSEARCH TECHNOLOGY	141
<i>TABLE 69 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT</i>	142
APPROVALS	142
RECENT STUDIES	143
Tumor Cell (CTC) Enumeration Using Cellsearch	143
CELLSEARCH IN CHINA	144
VERIDEX AND MASSACHUSETTS GENERAL HOSPITAL COLLABORATION	145
POSSIBLE USE OF CTC'S AND DTC'S AS NEW BIOMARKERS	146
EPISPOT	147
CLINICAL APPLICATIONS	147
<i>TABLE 70 EPISPOT: CLINICAL TRIALS FOR DETECTION OF CTC'S</i>	148
Descriptions of Clinical Trials	148
NCT01402154 Trial	148
NCT01558349 Trial	148
NCT01596790 Trial	148
<i>TABLE 71 OUTCOME MEASUREMENTS NCT01596790 TRIAL</i>	149
ApoCell	149
ApoCell and Transgenomic Present Results of Lung Cancer Research Study	149
ApoCell's CTC Capture Technology Detects and Recovers Deadly Liver Cancer Cells	150
Nektar's Ongoing Phase 3 BEACON Study	150
APPLICATIONS	151
Application of iCTC Detection and Culture in Personalized Cancer Management	151
Stony Brook University Medical Center	151
Microfluidic Sorting of Blood Cells for Cellular and Molecular Analysis	152
Cancer Sample Preparation with Micromachined Magnetic Sifter and Nanoparticles	152
Stanford Center for Magnetic Nanotechnology	152
The Scripps Research Institute: The Fluid Phase of Solid Tumors	152
ApoCell - Utilization of Dielectrophoresis for Antigen-Independent CTC Capture Allows for Detection of Heterogeneous Tumor Cell Populations	152
APPLICATION OF CTC TECHNOLOGIES TO CLINICAL TESTING	153
CTC TECHNOLOGIES FOR CLINICAL DEVELOPMENT	154
Practical Application	154



<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 72 CTC ASSAY CLINICAL READINESS EVALUATION</i>	155
<i>TABLE 73 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS</i>	156
STANDARD RECOMMENDATIONS	156
Specificity of a CTC Assay	157
Clinical Trial Design Considerations	158
<i>TABLE 74 CTC QUALIFICATION STUDIES</i>	158
SWOG S0500 Trial	159
Study Strategy and Process	159
CTC NUMBER AS A PROGNOSTIC BIOMARKER	161
Breast Cancer	161
Metastatic Castrate-resistant Prostate Cancer	161
Colorectal Cancer	162
Lung Cancer	162
PROGNOSTIC STUDIES	162
CTC'S AS A SURROGATE RESPONSE BIOMARKER	163
CTC'S AS A REAL-TIME BIOPSY	163
CTC CHIP TECHNOLOGY AND EGFR MUTATION ANALYSIS	164
CTC CHARACTERIZATION AFTER ENRICHMENT USING THE CELLSEARCH PLATFORM	164
FINAL REMARKS	165
CHAPTER 8 CIRCULATING TUMOR CELL MARKET	167
THE INVASIVE CANCER!	167
<i>TABLE 75 GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS)</i>	167
<i>FIGURE 13 GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS)</i>	167
CANCER SURVIVAL	168
<i>TABLE 76 GLOBAL CANCER SURVIVORS, 2008 (MILLIONS)</i>	169
<i>FIGURE 14 GLOBAL CANCER SURVIVORS 2008 (MILLIONS)</i>	169
<i>TABLE 77 UNITED STATES CANCER SURVIVORS, 2008-2022 (MILLIONS)</i>	169
<i>TABLE 78 MALE CANCER SURVIVORS (%)</i>	170
<i>TABLE 79 FEMALE CANCER SURVIVORS (%)</i>	170
GLOBAL ANNUAL ONCOLOGY MARKET	171
CANCER THERAPY	172
<i>TABLE 80 MAJOR PLAYERS</i>	172
<i>TABLE 81 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	173
<i>FIGURE 15 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	173
AGING AND CANCER	174
CANCER DRUG PIPELINE	174
<i>TABLE 82 DRUGS APPROVED IN 2013</i>	175
CANCER COSTS IN THE U.S.	175
<i>TABLE 83 CANCER FORECAST IN U.S., 2020 - KEY FACTS</i>	176
<i>TABLE 84 CANCER CARE COST IN U.S., 2010 AND 2020 (\$ BILLIONS)</i>	177
BREAST CANCER	177
Treatment and Survival	177
Common Side Effects of Treatment	178
COLON AND RECTUM	179

<b>TOPIC</b>	<b>PAGE NO.</b>
Treatment and Survival	179
Common Side Effects of Treatment	179
PROSTATE	180
Treatment and Survival	180
Common Side Effects of Treatment	180
CHEMOTHERAPY MARKET	180
CANCER TESTING MARKET	181
<i>TABLE 85 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST THROUGH 2018 (\$ MILLIONS)</i>	181
<i>FIGURE 16 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST 2012-2018 (\$ MILLIONS)</i>	181
<i>TABLE 86 CANCER TESTING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	183
<i>FIGURE 17 CANCER TESTING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	183
<i>TABLE 87 KEY PLAYERS</i>	184
IVD Market in China	185
CURRENT CANCER DIAGNOSTIC TESTS	186
Cancer Testing in Developing Nations	186
New Opportunities	186
<i>TABLE 88 SIGNIFICANT DEVELOPMENTS IN CANCER FOLLOW-UP</i>	187
A UNIVERSAL TUMOR TEST- IS IT POSSIBLE?	187
<i>TABLE 89 CANCER TESTS AND LIMITATIONS - THE CASE AGAINST DEVELOPMENT OF A UNIVERSAL TEST</i>	188
CANCER BIOMARKER TESTING MARKET	188
<i>TABLE 90 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	188
<i>FIGURE 18 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	188
<i>TABLE 91 THE KEY PLAYERS</i>	189
<i>TABLE 92 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	190
<i>FIGURE 19 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	190
MOLECULAR DIAGNOSTICS	191
<i>TABLE 93 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	191
<i>FIGURE 20 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	191
CANCER BIOMARKER TESTS	192
CANCER DISEASE MANAGEMENT	192
PERSONALIZED CANCER TESTING	192
Cancer Testing Competitors	192
CIRCULATING TUMOR CELL MARKET - A NEW APPROACH	193
<i>TABLE 94 CTC'S - DIFFERENTIATING FEATURES</i>	194
CTCs Advantages	194
THE CLINICAL DIAGNOSTICS MARKET	195
Market Opportunities	195
<i>TABLE 95 STEM CELL MARKET OVERVIEW</i>	196
<i>TABLE 96 KEY COMPANIES SELLING STEM CELL RESEARCH PRODUCTS</i>	196
CTC Testing	197
<i>TABLE 97 CTC COMPANIES WITH PROMISING PRODUCTS</i>	197

<b>TOPIC</b>	<b>PAGE NO.</b>
CellSearch CTC test	198
<i>TABLE 98 CLINICAL USE OF CELLSEARCH SYSTEM</i>	198
AdnaTest	198
CURRENT STATUS OF THE MARKET	198
<i>TABLE 99 PRICING (DOLLARS)</i>	199
<i>TABLE 100 CELLSEARCH KIT</i>	199
Updated Coding and Payment for Circulating Tumor Cell Testing	200
Global Market for Circulating Cancer Cells (CTCs)	200
<i>TABLE 101 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	201
<i>FIGURE 21 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, 2012-2018 (\$ MILLIONS)</i>	201
<i>TABLE 102 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	202
<i>FIGURE 22 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, 2012-2018 (\$ MILLIONS)</i>	203
<i>TABLE 103 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	204
<i>FIGURE 23 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, 2012-2018 (\$ MILLIONS)</i>	204
<i>TABLE 104 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	205
<i>FIGURE 24 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER - SALES AND FORECAST BY REGION, 2012-2018 (\$ MILLIONS)</i>	205
United States Market for Circulating Cancer Cells (CTCs)	206
<i>TABLE 105 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	207
<i>FIGURE 25 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	207
TIMELINE	207
<i>TABLE 106 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION, SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	208
<i>FIGURE 26 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	208
Europe - Market for Circulating Cancer Cells (CTCs)	208
<i>TABLE 107 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	209
<i>FIGURE 27 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	209
<i>TABLE 108 EUROPEAN CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	210
Rest of World Market for Circulating Cancer Cells (CTCs)	210
<i>TABLE 109 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	210
<i>FIGURE 28 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	211
Canada	211
<i>TABLE 110 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	212
<i>FIGURE 29 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	212

<b>TOPIC</b>	<b>PAGE NO.</b>
ASIA-PACIFIC SOLID TUMORS MARKET	212
FUTURE AND NEXT STEPS	213
CHAPTER 9 PATENTS	216
<i>TABLE 111 CIRCULATING TUMOR CELL ASSAY CHARACTERISTICS</i>	216
KEY PATENTS	216
<i>TABLE 112 CTC PATENTS</i>	217
VERIDEX	218
EpCAM Based Enrichment Using Magnetic Beads	218
MAGSWEEPER	218
EpCAM Based Magnetic Beads	218
SCRIPPS RESEARCH INSTITUTE (EPIC SCIENCES)	219
HD-CTC Technology	219
CELLPOINT DIAGNOSTICS	219
ON-Q-ITY	219
BIOFLUIDICA	219
ADNAGEN	220
Multiple Antibodies on Magnetic Beads	220
FILTINI	220
3D Parylene Membrane Filter for Isolation of CTC	220
IKONISYS	220
AVIVA BIOSCIENCES	221
Methods, Compositions, and Automated Systems for Separating Rare Cells	221
<i>TABLE 113 KEY PATENTS BY AVIVA BIOSCIENCES</i>	221
HARVARD UNIVERSITY - MEHMET TONER, PHD	221
Microposts Coated with EpCAM	221
CELLECTIVE DX	222
Maternal Displacement Obstacle Chip	222
JOHNS HOPKINS UNIVERSITY	222
Antibody-Coated Microfluidic Chip and Quantum Dots-Based Imaging	222
MEDICAL DISCOVERY PARTNERS	222
RBC Agglutination Followed by Filtration	222
CYNVENIO BIOSYSTEMS	222
Microfluidic Sheath Flow for Cell Isolation	222
SCREENCELL	223
BIOCEPT	223
Recovery of Rare Cells Using a Microchannel Apparatus with Patterned Posts	223
CANOPUS BIOSCIENCE	223
Enrichment Technology Is Now Protected by Key Patents	223
ADVANCED CELL DIAGNOSTICS	224
CHAPTER 10 SELECTED COMPANY PROFILES	226
COMPANIES	226
KEY PLAYERS	226
<i>TABLE 114 COMMERCIAL CIRCULATING TUMOR CELL TECHNOLOGY PLATFORMS</i>	226
KEY COMPANY PROFILES	227

<b>TOPIC</b>	<b>PAGE NO.</b>
ADNAGEN	227
ADVANCED CELL DIAGNOSTICS	227
APOCELL	228
AVIVA BIOSCIENCES	228
BIOCEP LTD.	229
BIOCEPT INC.	229
BIOFLUIDICA MICROT TECHNOLOGIES LLC	230
CANOPUS BIOSCIENCES	230
CELLTRAFIX INC.	230
CELULA	231
CLEARBRIDGE BIOMEDICS	231
CREATV MICROT ECH INC	232
CYNVENIO BIOSYSTEMS, INC.	232
EPIC BIOSCIENCES	232
FILTINI INC.	233
FLUXION BIOSCIENCES	233
GREINER BIO-ONE GMBH	233
IKONISYS INC.	234
IVDIAGNOSTICS INC.	234
JANSSEN DIAGNOSTICS	234
MILTENYI BIOTECH	234
NANOSTRING TECHNOLOGIES INC.	235
NATURAL NANO INC.	235
ONCO VISTA	235
ON-Q-ITY	235
RARECELLS	236
SCREENCELL	236
SILICON BIOSYSTEMS USA	237
STEMCELL TECHNOLOGIES	237
SYNERGEX CORPORATION	237
SYSMEX CORPORATION	238
VERIDEX, LLC	238
VITATEX INC.	239
CHAPTER 11 REFERENCES	241

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 CATEGORIES OF STEM CELLS	14
TABLE 2 PRODUCT CATEGORIES	15
TABLE 3 KEY FACTORS OF CTC'S	16
TABLE 4 CIRCULATING TUMOR CELLS - FEATURES	18
TABLE 5 METASTATIC CASCADE	24
TABLE 6 EPCAM-BASED ASSAYS	26
TABLE 7 CTC DETECTION - ADVANTAGES	29
TABLE 8 CANCER - KEY FACTS	32
TABLE 9 CANCER CAUSES	33
TABLE 10 CANCER CAUSING FACTORS	34
TABLE 11 CANCER SCREENING METHODS	35
TABLE 12 NONCOMMUNICABLE DISEASES ACTION PLAN	36
TABLE 13 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)	37
TABLE 14 ESTIMATED GLOBAL CANCER INCIDENCE, 2008 (THOUSANDS)	38
TABLE 15 INCREASE IN CANCER BURDEN - FACTORS	41
TABLE 16 THE MAIN TYPES OF CANCER AND ASSOCIATED MORTALITY	43
TABLE 17 GENERAL GLOBAL CANCER INCIDENCE BY TYPE	43
TABLE 18 GLOBAL INCIDENCE OF CANCER BY TYPE, 2008 (THOUSANDS/%)	44
TABLE 19 CANCER INCIDENCE IN MEN, 2008 (THOUSANDS/%)	45
TABLE 20 CANCER INCIDENCE IN WOMEN, 2008 (THOUSANDS/%)	46
TABLE 21 GLOBAL INCIDENCE OF CANCER IN DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000, 2008	47
TABLE 22 GLOBAL INCIDENCE OF CANCER IN MEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008	48
TABLE 23 GLOBAL INCIDENCE OF CANCER IN WOMEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008	49
TABLE 24 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013	50
TABLE 25 GLOBAL BREAST CANCER FACTS	51
TABLE 26 BREAST CANCER IN THE UNITED STATES	52
TABLE 27 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN MEN, 2008	54
TABLE 28 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN WOMEN, 2008	55
TABLE 29 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013	55
TABLE 30 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF PROSTATE CANCER, 2008	56
TABLE 31 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)	58
TABLE 32 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008	60
TABLE 33 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030 (NUMBER)	62
TABLE 34 PROSTATE CANCER CASES AND DEATHS IN THE U.S. 2008-2011 (NUMBER)	63
TABLE 35 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030 (NUMBER)	64
TABLE 36 PROSTATE CANCER INCIDENCE RATES IN THE U.S. BY RACE, 2005-2009 (PER 100,000 MEN)	65

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 37 ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030 (NUMBER)	65
TABLE 38 MORTALITY RATES BY RACE IN U.S., 2005-2009	66
TABLE 39 ESTIMATED PROSTATE CANCER IN CANADA, 2012 (NUMBER)	67
TABLE 40 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION, 2008	68
TABLE 41 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION)	70
TABLE 42 POTENTIAL APPLICATIONS OF CTC-BASED DIAGNOSTICS	74
TABLE 43 CLINICAL RELEVANCE OF CTC	78
TABLE 44 CTC ENRICHMENT METHODS	78
TABLE 45 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ENRICHMENT	80
TABLE 46 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ANALYSIS	84
TABLE 47 ENUMERATION TECHNIQUES	86
TABLE 48 FUNCTIONAL ASSAYS	90
TABLE 49 KEY FACTS ABOUT CIRCULATING TUMOR CELLS	97
TABLE 50 MICRO-COUNT FEATURES A NEW TECHNOLOGY	98
TABLE 51 CTC ASSAY PRE-ANALYTICAL VALIDATION CONSIDERATIONS	102
TABLE 52 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS	102
TABLE 53 CTC ASSAY POST-ANALYTICAL VALIDATION CONSIDERATIONS	103
TABLE 54 CURRENT ENRICHMENT ASSAYS FOR CTC'S	105
TABLE 55 CTC ENUMERATION ASSAYS	108
TABLE 56 CHARACTERIZATION ASSAYS FOR CTC'S	111
TABLE 57 KEY FEATURES-IVD CTC TESTS	112
TABLE 58 TUMOR TYPES: PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010	112
TABLE 59 PROSTATE CANCER DIAGNOSIS AND ROLE OF CTC'S	115
TABLE 60 CURRENT DIAGNOSTIC METHODS	115
TABLE 61 APOSTREAM KEY FEATURES	116
TABLE 62 CANOPUS BIOSCIENCE TECHNOLOGY - BENEFITS	118
TABLE 63 CELLOPTICS' CANCER APPLICATION	118
TABLE 64 CELLOPTICS' KEY FEATURES - ENRICHMENT	119
TABLE 65 CELLOPTICS' KEY FEATURES - LABELING	119
TABLE 66 CELLOPTICS' KEY FEATURES - DETECTION	120
TABLE 67 ISET TEST - SPECIFICATIONS	120
TABLE 68 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT	137
TABLE 69 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT	142
TABLE 70 EPISPOT: CLINICAL TRIALS FOR DETECTION OF CTC'S	148
TABLE 71 OUTCOME MEASUREMENTS NCT01596790 TRIAL	149
TABLE 72 CTC ASSAY CLINICAL READINESS EVALUATION	155
TABLE 73 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS	156
TABLE 74 CTC QUALIFICATION STUDIES	158
TABLE 75 GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS)	167
TABLE 76 GLOBAL CANCER SURVIVORS, 2008 (MILLIONS)	169
TABLE 77 UNITED STATES CANCER SURVIVORS, 2008-2022 (MILLIONS)	169
TABLE 78 MALE CANCER SURVIVORS (%)	170
TABLE 79 FEMALE CANCER SURVIVORS (%)	170
TABLE 80 MAJOR PLAYERS	172

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 81 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	173
TABLE 82 DRUGS APPROVED IN 2013	175
TABLE 83 CANCER FORECAST IN U.S., 2020 - KEY FACTS	176
TABLE 84 CANCER CARE COST IN U.S., 2010 AND 2020 (\$ BILLIONS)	177
TABLE 85 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST THROUGH 2018 (\$ MILLIONS)	181
TABLE 86 CANCER TESTING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	183
TABLE 87 KEY PLAYERS	184
TABLE 88 SIGNIFICANT DEVELOPMENTS IN CANCER FOLLOW-UP	187
TABLE 89 CANCER TESTS AND LIMITATIONS - THE CASE AGAINST DEVELOPMENT OF A UNIVERSAL TEST	188
TABLE 90 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	188
TABLE 91 THE KEY PLAYERS	189
TABLE 92 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	190
TABLE 93 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	191
TABLE 94 CTC'S - DIFFERENTIATING FEATURES	194
TABLE 95 STEM CELL MARKET OVERVIEW	196
TABLE 96 KEY COMPANIES SELLING STEM CELL RESEARCH PRODUCTS	196
TABLE 97 CTC COMPANIES WITH PROMISING PRODUCTS	197
TABLE 98 CLINICAL USE OF CELLSEARCH SYSTEM	198
TABLE 99 PRICING (DOLLARS)	199
TABLE 100 CELLSEARCH KIT	199
TABLE 101 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)	201
TABLE 102 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)	202
TABLE 103 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)	204
TABLE 104 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 (\$ MILLIONS)	205
TABLE 105 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	207
TABLE 106 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION, SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	208
TABLE 107 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	209
TABLE 108 EUROPEAN CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	210
TABLE 109 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	210
TABLE 110 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	212
TABLE 111 CIRCULATING TUMOR CELL ASSAY CHARACTERISTICS	216
TABLE 112 CTC PATENTS	217
TABLE 113 KEY PATENTS BY AVIVA BIOSCIENCES	221
TABLE 114 COMMERCIAL CIRCULATING TUMOR CELL TECHNOLOGY PLATFORMS	226



**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, 2012-2018 (\$ MILLIONS)	8
FIGURE 1 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)	37
FIGURE 2 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013	50
FIGURE 3 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013	56
FIGURE 4 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)	58
FIGURE 5 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008	61
FIGURE 6 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030 (NUMBER)	62
FIGURE 7 PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011 (NUMBER)	63
FIGURE 8 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030 (NUMBER)	64
FIGURE 9 ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030 (NUMBER)	66
FIGURE 10 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008	68
FIGURE 11 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION)	71
FIGURE 12 TUMOR TYPES - PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010	113
FIGURE 13 GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS)	167
FIGURE 14 GLOBAL CANCER SURVIVORS 2008 (MILLIONS)	169
FIGURE 15 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	173
FIGURE 16 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST 2012-2018 (\$ MILLIONS)	181
FIGURE 17 CANCER TESTING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	183
FIGURE 18 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	188
FIGURE 19 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	190
FIGURE 20 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	191
FIGURE 21 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, 2012-2018 (\$ MILLIONS)	201
FIGURE 22 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, 2012-2018 (\$ MILLIONS)	203
FIGURE 23 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, 2012-2018 (\$ MILLIONS)	204
FIGURE 24 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER - SALES AND FORECAST BY REGION, 2012-2018 (\$ MILLIONS)	205
FIGURE 25 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	207
FIGURE 26 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	208
FIGURE 27 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	209
FIGURE 28 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	211

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 29 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	212